Find a Cancer Provider

Are you a referring physician?
within
I am searching for a
Reset Form
Christine A. Ciunci, MD, MSCE

Christine A. Ciunci, MD, MSCE Physician

Interim Chief of Hematology Oncology, Abramson Cancer Center at Penn Presbyterian Medical Center Physician Lead for the Cancer Service Line at Penn Presbyterian Medical Center Assistant Professor of Clinical Medicine Assistant Professor of Clinical Medicine

Dr. Ciunci is employed by Penn Medicine.

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2017
  • Internal Medicine, 2011
  • Medical Oncology, 2016

Clinical Expertise:

  • Adenocarcinoma of Lung
  • ALK Translocation
  • Asbestosis
  • Biological Targeted Therapy
  • Cancer Chemotherapy
  • Cancer of the Mediastinum
  • Chemoradiation
  • Chest Wall Tumors
  • Combined Modality Therapy
  • Diaphragm Tumor
  • EGFR Mutation
  • EGFR Translocation
  • Immunotherapy
  • Inherited Lung Cancer Risk
  • Kras Mutation
  • Large Cell Cancer of the Lung
  • Lung Carcinoid Tumor
  • Lung Lesion
  • Lung Nodule
  • Non-Small Cell Lung Cancer
  • Pleural Cancer
  • RET Mutation
  • ROS1 Fusion
  • Small Cell Lung Cancer
  • Squamous Cancer of the Lung
  • Thoracic Cancer
  • Thymoma and Thymic Carcinoma
  • Thymus Cancer
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oscar Health Plan of PA (DO NOT USE)
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Temple University School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Society of Clinical Oncology, National

Hospital Affiliation

Dr. Ciunci is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

thoracic malignancies
lung cancer

Selected Publications:

Grewal AS, Min EJ, Long Q, Grewal SK, Jain V, Levin WP, Cengel KA, Swisher-McClure S, Aggarwal C, Bauml JM, Singh A, Ciunci C, Cohen RB, Langer C, Feigenberg SJ, Berman AT.: Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy: Tumor Regression Predicts Outcomes in LA-NSCLC. Int J Radiat Oncol Biol Phys. pii: S0360-3016 (19): 33901-X,2019.

Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen RB, Langer CJ.: Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncol. : 2019.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.: Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. J Natl Cancer Inst. 111 (5): 490-497,2019.

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.: Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 5 (2): 173-180,2019.

Bange E, Marmarelis ME, Hwang WT, Yang YX, Thompson JC, Rosenbaum J, Bauml JM, Ciunci C, Alley EW, Cohen RB, Langer CJ, Carpenter E, Aggarwal C.: Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 3 : 2019.

Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter EL, Langer CJ.: Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol : 2018.

Evans T, Ciunci C, Hertan L, Gomez D.: Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Transl Lung Cancer Res. 6 (2): 119-130,2017.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106 : 1-7,2017.

Chao HH, Berman AT, Simone CB, Ciunci C, Gabriel P, Lin H, Both S, Langer C, Lelionis K, Rengan R, Hahn SM, Prabhu K, Fagundes M, Hartsell W, Mick R, Plastaras JP.: Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol. 12 (2): 281-292,2017.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.: Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 22 (23): 5772-5782,2016.

Academic Contact Info

Abramson Cancer Center
Penn Presbyterian Medical Center
Cupp Building 1st Floor
51 N 39th Street

Philadelphia, PA 19104
Phone: (215) 662-9801
Patient appointments: 800-789-7366 (PENN)